Quantitative and Qualitative Differences in Response to Influenza and Pneumococcal Vaccines
News Apr 23, 2013
Investigators at the Baylor Institute for Immunology Research in Dallas and the Benaroya Research Institute (BRI) in Seattle have used systems immunology and genome-wide profiling to characterize the immune responses elicited by two popular vaccines. They also developed interactive, web-based figures and data exploration tools to share their findings with the broader scientific community. This NIAID-funded work, described online in the April 18, 2013, issue of Immunity, not only provides new insights into how vaccines confer protective immunity, but also demonstrates the potential of web technologies in disseminating the large amounts of data generated by systems immunology research.
For the full study, please visit http://www.niaid.nih.gov/LabsAndResources/resources/bioinformatics/Pages/vaccImmResponses.aspx
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE
Fight Against Cancer: Drug Combination Helps Kickstart the Immune SystemNews
Scientists from King's College London have found a way to boost the immune system to help it fight back against cancer.
The breakthrough involves the first ever use of a combination of chemotherapy and a drug being trialled as a treatment for neonatal jaundice, that together help kick start the body's natural defences.